February 23, 2006—An experimental gel version of the HIV med Viread (tenofovir) caused no adverse side effects when used as a vaginal microbicide in tests on women, according to a report in the medical journal AIDS. Next up: A look at the gel’s ability to block HIV transmission—which it has already done on monkeys.